Not wellness.
Science.
This editorial library summarises selected research related to the panel catalog and educational content. It does not provide individual clinical guidance, and a panel does not establish treatment eligibility, safety, or efficacy.
GLP-1 Metabolic Monitoring
STEP 1 trial (Wilding et al, NEJM 2021): 14.9% mean body weight loss on semaglutide 2.4mg vs 2.4% on placebo over 68 weeks
Evidence Boundaries
Preclinical, observational, and controlled human evidence answer different questions. None of these summaries establishes an individual treatment recommendation.
Outside Biological-Age Research
GrimAge is a research epigenetic model; reported performance depends on the population, assay, methods, and comparison model (Lu et al, 2019)
Key studies
| Study | Author / Journal | Study design | Reported finding |
|---|---|---|---|
| STEP 1 Obesity Trial (2021) | Wilding et al · NEJM | Randomised trial, 68 weeks | 14.9% mean body weight loss |
| Epigenetic Ageing & Mortality (2019) | Lu et al · Aging (Albany NY) | DNA-methylation research (outside assay) | Reported population-level outcome associations |
Proposed evidence-review standard
Before any clinical launch, an identified physician owner must approve a documented literature-review method and the sources used for each clinical claim or service.
Preclinical, observational, and controlled human evidence must be clearly distinguished. Editorial summaries cannot substitute for individual clinical evaluation.
Clinical versioning, change control, patient communication, and periodic review remain launch requirements rather than current WellSpry services.
Review the catalog-listed markers
WellSpry's widest published panel lists 18 catalog-listed markers; additional values require outside testing. A panel does not establish treatment eligibility, safety, or efficacy. Panels can be purchased through WellSpry; Choose Health handles patient activation, consent, lab processing, clinician review, notification, and secure portal delivery. WellSpry Protocol Management and prescribing remain unavailable.
Explore Testing Panels